{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T11:59:25Z","timestamp":1795089565311,"version":"4.10.2"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T00:00:00Z","timestamp":1598832000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T00:00:00Z","timestamp":1598832000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Role of tumor markers in gall bladder carcinoma (GBC) is not well established. We evaluated the prognostic value of carbohydrate antigen 19\u20139 (CA19\u20139) and carcinoma embryonic antigen (CEA) in patients with GBC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Of the 225 patients of GBC enrolled,176 patients were included in the study (excluded 49 patients with jaundice). Patients were divided into 3 groups; resectable\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200992, unresectable\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200917, metastatic\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200967. The clinico-pathological characteristics, tumor markers and survival data were analysed. The cutoff values of CA19\u20139 &amp; CEA for predicting metastases were computed using receiver operating characteristic curve. Kaplan Meir survival and Cox regression analysis were done for factors predicting survival and recurrence.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The median value of Ca19\u20139 was significantly higher in metastatic group [resectable: 21.3, unresectable: 53.9 and metastatic: 79;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001] but not for CEA [3.5, 7.8 and 5\u2009ng\/ml (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.20)]. A cutoff value of 72\u2009IU\/ml for CA19\u20139, 5\u2009ng\/ml for CEA had a sensitivity and specificity of 52 and 80%, 51 and 72% respectively for detection of metastatic disease. Median, 3-year &amp; 5-year survival were significantly lower in patients with CEA\u2009&gt;\u20094 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.041), Ca19.9\u2009&gt;\u200937 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.019), T3\/T4 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001), node positive (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001) and presence of perineural invasion (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001). However, on multivariate analysis, only Ca19.9\u2009&gt;\u200937 predicted recurrence (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002, HR 5.8).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Raised CA19.9 and CEA predict metastatic disease in patients with GBC without jaundice with a high specificity and may help in prognostication of the patient. CA19\u20139 was better than CEA in prediction of tumor burden and in predicting recurrence.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-020-07334-x","type":"journal-article","created":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T06:03:10Z","timestamp":1598853790000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["Raised CA19\u20139 and CEA have prognostic relevance in gallbladder carcinoma"],"prefix":"10.1186","volume":"20","author":[{"given":"Ashish","family":"Sachan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sundeep Singh","family":"Saluja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phani Kumar","family":"Nekarakanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Nimisha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhawna","family":"Mahajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirdaya H.","family":"Nag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pramod K.","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,31]]},"reference":[{"key":"7334_CR1","first-page":"99","volume":"6","author":"R Hundal","year":"2014","unstructured":"Hundal R, Shaffer EA. Gallbladder cancer: epidemiology and outcome. Clin Epidemiol. 2014;6:99\u2013109.","journal-title":"Clin Epidemiol"},{"key":"7334_CR2","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1245\/ASO.2004.03.011","volume":"11","author":"WG Hawkins","year":"2004","unstructured":"Hawkins WG, DeMatteo RP, Jarnagin WR, Ben-Porat L, Blumgart LH, Fong Y. Jaundice predicts advanced disease and early mortality in patients with gallbladder cancer. Ann Surg Oncol. 2004;11:310\u20135.","journal-title":"Ann Surg Oncol"},{"key":"7334_CR3","doi-asserted-by":"publisher","first-page":"74","DOI":"10.2214\/AJR.07.2348","volume":"190","author":"SJ Kim","year":"2008","unstructured":"Kim SJ, Lee JM, Lee JY, et al. Accuracy of preoperative T-staging of gallbladder carcinoma using MDCT. AJR Am J Roentgenol. 2008;190:74\u201380.","journal-title":"AJR Am J Roentgenol"},{"key":"7334_CR4","doi-asserted-by":"crossref","unstructured":"Mishra PK, Saluja SS, Prithiviraj N. Etal. Predictors of curative resection and long term survival of gall bladder cancer- a retrospective analysis. Am J Surg. 2017;214(2):278\u201386.","DOI":"10.1016\/j.amjsurg.2017.02.006"},{"key":"7334_CR5","unstructured":"National Comprehensive Cancer Network. Hepatobiliary cancer( version 2.2017). 2017."},{"key":"7334_CR6","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/j.1477-2574.2009.00149.x","volume":"12","author":"I Hatzaras","year":"2010","unstructured":"Hatzaras I, Schmidt C, Muscarella P, Melvin WS, Ellison EC, Bloomston M, et al. Elevated CA 19-9 portends poor prognosis inpatients undergoing resection of biliary malignancies. HPB. 2010;12:134\u20138.","journal-title":"HPB"},{"key":"7334_CR7","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1002\/ijc.2910450505","volume":"45","author":"BL Strom","year":"1990","unstructured":"Strom BL, Maislin G, West SL, Atkinson B, Herlyn M, Saul S, et al. Serum CEA and CA 19-9: potential future diagnostic or screening tests for gallbladder cancer? Int J Cancer. 1990;45:821\u20134.","journal-title":"Int J Cancer"},{"issue":"8","key":"7334_CR8","doi-asserted-by":"publisher","first-page":"e14550","DOI":"10.1097\/MD.0000000000014550","volume":"98","author":"F Liu","year":"2019","unstructured":"Liu F, Hu HJ, Ma WJ, Yang Q, Wang JK, Li FY. Prognostic significance ofneutrophil-lymphocyte ratio and carbohydrate antigen 19-9 in patients withgallbladder carcinoma. Medicine (Baltimore). 2019 Feb;98(8):e14550.","journal-title":"Medicine (Baltimore)"},{"key":"7334_CR9","doi-asserted-by":"publisher","first-page":"4085","DOI":"10.3748\/wjg.v20.i14.4085","volume":"20","author":"YF Wang","year":"2014","unstructured":"Wang YF, Feng FL, Zhao XH, et al. Combined detection tumor markers for diagnosis and prognosis of gallbladder cancer. World J Gastroenterol. 2014;20:4085\u201392.","journal-title":"World J Gastroenterol"},{"key":"7334_CR10","first-page":"1","volume-title":"Elevation of CA19\u20139 and CEA is associated with a poor prognosis in patients with resectable gallbladder carcinoma, HPB","author":"Z Wen","year":"2017","unstructured":"Wen Z, et al. Elevation of CA19\u20139 and CEA is associated with a poor prognosis in patients with resectable gallbladder carcinoma, HPB; 2017. p. 1\u20136."},{"key":"7334_CR11","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/978-3-319-40618-3_24","volume-title":"AJCC Cancer staging manual","author":"AX Zhu","year":"2017","unstructured":"Zhu AX, Pawlik TM, Kooby DA, Schefter TE, Vauthey J-N. Gallbladder. In: AJCC Cancer staging manual. 8th ed. New York: Springer International Publishing; 2017. p. 303\u20139.","edition":"8"},{"key":"7334_CR12","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.3760\/cma.j.issn.0366-6999.20131734","volume":"127","author":"T Yu","year":"2014","unstructured":"Yu T, Yu H, Cai X. Preoperative prediction of survival in resectablegallbladder cancer by a combined utilization of CA 19-9 andcarcinoembryonic antigen et al. Chin Med J. 2014;127:2299\u2013303.","journal-title":"Chin Med J"},{"issue":"3","key":"7334_CR13","doi-asserted-by":"publisher","first-page":"E76","DOI":"10.1111\/ans.14893","volume":"89","author":"F Liu","year":"2019","unstructured":"Liu F, Wang JK, Ma WJ, Yang Q, Hu HJ, Li FY. Clinical value of preoperativeCA19-9 levels in evaluating resectability of gallbladder carcinoma. ANZ J Surg. 2019 Mar;89(3):E76\u201380.","journal-title":"ANZ J Surg"},{"issue":"11","key":"7334_CR14","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.1245\/s10434-008-9917-y","volume":"15","author":"PJ Shukla","year":"2008","unstructured":"Shukla PJ, Neve R, Barreto SG, Hawaldar R, Nadkarni MS, Mohandas KM, Shrikhande SV. A new scoring system for gallbladder cancer (aiding treatment algorithm): an analysis of 335 patients. Ann Surg Oncol. 2008 Nov;15(11):3132\u20137.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"7334_CR15","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jamcollsurg.2007.07.002","volume":"206","author":"CU Corvera","year":"2008","unstructured":"Corvera CU, Blumgart LH, Akhurst T, DeMatteo RP, D'Angelica M, Fong Y, Jarnagin WR. 18F-fluorodeoxyglucose positron emission tomography influences management decisions in patients with biliary cancer. J Am Coll Surg. 2008 Jan;206(1):57\u201365.","journal-title":"J Am Coll Surg"},{"issue":"1","key":"7334_CR16","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jhep.2006.03.009","volume":"45","author":"H Petrowsky","year":"2006","unstructured":"Petrowsky H, Wildbrett P, Husarik DB, Hany TF, Tam S, Jochum W, Clavien PA. Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma. J Hepatol. 2006 Jul;45(1):43\u201350.","journal-title":"J Hepatol"},{"issue":"2","key":"7334_CR17","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1007\/s12029-016-9914-5","volume":"49","author":"S Agrawal","year":"2018","unstructured":"Agrawal S, Lawrence A, Saxena R. Does CA 19-9 Have Prognostic Relevance in Gallbladder Carcinoma (GBC)? J Gastrointestinal Cancer. 2018 Jun 1;49(2):144\u20139.","journal-title":"J Gastrointestinal Cancer"},{"issue":"6","key":"7334_CR18","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1245\/s10434-010-1529-7","volume":"18","author":"MJ Chung","year":"2011","unstructured":"Chung MJ, Lee KJ, Bang S, Park SW, Kim KS, Lee WJ, Song SY, Chung JB, Park JY. Preoperative serum CA 19-9 level as a predictive factor for recurrence after curative resection in biliary tract cancer. Ann Surg Oncol. 2011 Jun 1;18(6):1651\u20136.","journal-title":"Ann Surg Oncol"},{"key":"7334_CR19","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1007\/s00432-019-03030-x","volume":"145","author":"N Golob-Schwarzl","year":"2019","unstructured":"Golob-Schwarzl N, Wodlej C, Kleinegger F, et al. Eukaryotic translation initiation factor 6 overexpression plays a major role in the translational control of gallbladder cancer. J Cancer Res Clin Oncol. 2019;145:2699\u2013711.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"52","key":"7334_CR20","doi-asserted-by":"publisher","first-page":"89736","DOI":"10.18632\/oncotarget.21116","volume":"8","author":"SM Kessler","year":"2017","unstructured":"Kessler SM, Lederer E, Laggai S, et al. IMP2\/IGF2BP2 expression, but not IMP1 and IMP3, predicts poor outcome in patients and high tumor growth rate in xenograft models of gallbladder cancer. Oncotarget. 2017;8(52):89736\u201345.","journal-title":"Oncotarget."},{"issue":"2","key":"7334_CR21","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.bbadis.2018.11.006","volume":"1865","author":"F Kleinegger","year":"2019","unstructured":"Kleinegger F, Hofer E, Wodlej C, et al. Pharmacologic IL-6R\u03b1 inhibition in cholangiocarcinoma promotes cancer cell growth and survival. Biochim Biophys Acta Mol basis Dis. 2019;1865(2):308\u201321.","journal-title":"Biochim Biophys Acta Mol basis Dis"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07334-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-020-07334-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07334-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T17:41:06Z","timestamp":1723484466000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-07334-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,31]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["7334"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-07334-x","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,31]]},"assertion":[{"value":"13 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Written informed patient consent was obtained for this research. Ethical approval was not required due to the retrospective nature of the study (Retrospective observational study). The Medical Council of India\u2019s Code of Medical Ethics permits waiver of ethics review in a retrospective study if the patient\u2019s identity is not revealed.[Reference<b>:<\/b> Medical Council of India. Indian Medical Council (Professional Conduct, Etiquette and Ethics) Regulations, 2002. Gazette of India dated 06.04.02, part III, section 4. [cited 2006 March 25] Available from:\n                      \n                      ].","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed patient consent was obtained for this research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"826"}}